A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: A case report

Kazuto Hayasaka; Masateru Takigawa; Atsushi Takahashi; Taishi Kuwahara; Kenji Okubo; Yasuaki Tanaka; Toru Misawa; Masafumi Mizusawa; Yosuke Yamakami; Keisuke Kojima; Yuichiro Sagawa; Keiichi Hishikari; Kazuya Yamao; Emiko Nakashima; Jun Nakajima; Shigeki Kimura; Katsumasa Takagi; Hiroyuki Hikita; Mitsuaki Isobe

doi:10.1016/j.jccase.2017.03.009

A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: A case report

Kazuto Hayasaka, Masateru Takigawa, Atsushi Takahashi, Taishi Kuwahara, Kenji Okubo, Yasuaki Tanaka, Toru Misawa, Masafumi Mizusawa, Yosuke Yamakami, Keisuke Kojima, Yuichiro Sagawa, Keiichi Hishikari, Kazuya Yamao, Emiko Nakashima, Jun Nakajima, Shigeki Kimura, Katsumasa Takagi, Hiroyuki Hikita, Mitsuaki Isobe

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Capecitabine is an oral fluoropyrimidine which can prolong QT interval. However, there have been no reports that capecitabine induced ventricular fibrillation (VF) due to secondary QT prolongation in patients with no structural heart disease. A 39-year-old woman developed VF during the chemotherapy of capecitabine for colon cancer. At the administration, corrected QT interval (QTc) was prolonged to 559 ms despite no evidence of organic heart disease. Discontinuation of capecitabline normalized the QTc (414 ms). During the follow-up of eight years, neither the QTc prolongation nor the recurrent VF has been detected. We report the rare case of capecitabine-related VF without any organic heart disease. <Learning objective: Capecitabine is an oral fluoropyrimidine carbamate commonly used to treat colorectal and breast cancer. Capecitabine has been reported to be associated with VF due to vasospasm. However, capecitabine is also associated with QT elongation. This is the first report to describe VF due to capecitabine-related secondary long QT syndrome in a patient with no cardiac heart disease. Physicians must carefully follow up patients during capecitabine chemotherapy with serial electrocardiograms.>

Original language	English
Pages (from-to)	26-29
Number of pages	4
Journal	Journal of Cardiology Cases
Volume	16
Issue number	1
DOIs	https://doi.org/10.1016/j.jccase.2017.03.009
Publication status	Published - Jul 2017
Externally published	Yes

Keywords

Capecitabine
Secondary long QT syndrome
Ventricular fibrillation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jccase.2017.03.009

Cite this

Hayasaka, K., Takigawa, M., Takahashi, A., Kuwahara, T., Okubo, K., Tanaka, Y., Misawa, T., Mizusawa, M., Yamakami, Y., Kojima, K., Sagawa, Y., Hishikari, K., Yamao, K., Nakashima, E., Nakajima, J., Kimura, S., Takagi, K., Hikita, H., & Isobe, M. (2017). A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: A case report. Journal of Cardiology Cases, 16(1), 26-29. https://doi.org/10.1016/j.jccase.2017.03.009

@article{bb9d4707c78c4c9c80f1a4b6a904f867,

title = "A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: A case report",

abstract = "Capecitabine is an oral fluoropyrimidine which can prolong QT interval. However, there have been no reports that capecitabine induced ventricular fibrillation (VF) due to secondary QT prolongation in patients with no structural heart disease. A 39-year-old woman developed VF during the chemotherapy of capecitabine for colon cancer. At the administration, corrected QT interval (QTc) was prolonged to 559 ms despite no evidence of organic heart disease. Discontinuation of capecitabline normalized the QTc (414 ms). During the follow-up of eight years, neither the QTc prolongation nor the recurrent VF has been detected. We report the rare case of capecitabine-related VF without any organic heart disease. ",

keywords = "Capecitabine, Secondary long QT syndrome, Ventricular fibrillation",

author = "Kazuto Hayasaka and Masateru Takigawa and Atsushi Takahashi and Taishi Kuwahara and Kenji Okubo and Yasuaki Tanaka and Toru Misawa and Masafumi Mizusawa and Yosuke Yamakami and Keisuke Kojima and Yuichiro Sagawa and Keiichi Hishikari and Kazuya Yamao and Emiko Nakashima and Jun Nakajima and Shigeki Kimura and Katsumasa Takagi and Hiroyuki Hikita and Mitsuaki Isobe",

note = "Publisher Copyright: {\textcopyright} 2017 Japanese College of Cardiology",

year = "2017",

month = jul,

doi = "10.1016/j.jccase.2017.03.009",

language = "English",

volume = "16",

pages = "26--29",

journal = "Journal of Cardiology Cases",

issn = "1878-5409",

publisher = "Elsevier Ltd.",

number = "1",

}

Hayasaka, K, Takigawa, M, Takahashi, A, Kuwahara, T, Okubo, K, Tanaka, Y, Misawa, T, Mizusawa, M, Yamakami, Y, Kojima, K, Sagawa, Y, Hishikari, K, Yamao, K, Nakashima, E, Nakajima, J, Kimura, S, Takagi, K, Hikita, H & Isobe, M 2017, 'A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: A case report', Journal of Cardiology Cases, vol. 16, no. 1, pp. 26-29. https://doi.org/10.1016/j.jccase.2017.03.009

TY - JOUR

T1 - A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation

T2 - A case report

AU - Hayasaka, Kazuto

AU - Takigawa, Masateru

AU - Takahashi, Atsushi

AU - Kuwahara, Taishi

AU - Okubo, Kenji

AU - Tanaka, Yasuaki

AU - Misawa, Toru

AU - Mizusawa, Masafumi

AU - Yamakami, Yosuke

AU - Kojima, Keisuke

AU - Sagawa, Yuichiro

AU - Hishikari, Keiichi

AU - Yamao, Kazuya

AU - Nakashima, Emiko

AU - Nakajima, Jun

AU - Kimura, Shigeki

AU - Takagi, Katsumasa

AU - Hikita, Hiroyuki

AU - Isobe, Mitsuaki

PY - 2017/7

Y1 - 2017/7

N2 - Capecitabine is an oral fluoropyrimidine which can prolong QT interval. However, there have been no reports that capecitabine induced ventricular fibrillation (VF) due to secondary QT prolongation in patients with no structural heart disease. A 39-year-old woman developed VF during the chemotherapy of capecitabine for colon cancer. At the administration, corrected QT interval (QTc) was prolonged to 559 ms despite no evidence of organic heart disease. Discontinuation of capecitabline normalized the QTc (414 ms). During the follow-up of eight years, neither the QTc prolongation nor the recurrent VF has been detected. We report the rare case of capecitabine-related VF without any organic heart disease.

AB - Capecitabine is an oral fluoropyrimidine which can prolong QT interval. However, there have been no reports that capecitabine induced ventricular fibrillation (VF) due to secondary QT prolongation in patients with no structural heart disease. A 39-year-old woman developed VF during the chemotherapy of capecitabine for colon cancer. At the administration, corrected QT interval (QTc) was prolonged to 559 ms despite no evidence of organic heart disease. Discontinuation of capecitabline normalized the QTc (414 ms). During the follow-up of eight years, neither the QTc prolongation nor the recurrent VF has been detected. We report the rare case of capecitabine-related VF without any organic heart disease.

KW - Capecitabine

KW - Secondary long QT syndrome

KW - Ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=85018320254&partnerID=8YFLogxK

U2 - 10.1016/j.jccase.2017.03.009

DO - 10.1016/j.jccase.2017.03.009

M3 - Article

AN - SCOPUS:85018320254

SN - 1878-5409

VL - 16

SP - 26

EP - 29

JO - Journal of Cardiology Cases

JF - Journal of Cardiology Cases

IS - 1

ER -

A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: A case report

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this